MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Archives & Legacy
Organization & Developments: Portola (Archives 2010-2016)
Parents
Archives & Legacy
Organization & Developments: Portola
Children
2010: Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban
2010: Portola Pharmaceuticals Enters Worldwide License Agreement with Novartis for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
2011: Biogen Idec, Inc. (Massachusetts) (BIIB), Portola Pharmaceuticals, Inc. Strike $553 Million Deal for Oral Syk Inhibitor (2011)
2012: During the first part of 2012 Portola also plans to start a Phase III betrixaban program to prevent venous thromboembolism in ill patients.
2016: Can 'Santa Claus' Rally Continue For These 3 Small Biotechs? - Portola, Synergy, Progenics
2016: Portola - Driving The Shift In The Anticoagulant Market - Portola Pharmaceuticals (NASDAQ:PTLA)
2016: Portola Pharmaceuticals - Liking The Risk-Reward For 2016 And Beyond - Portola Pharmaceuticals (NASDAQ:PTLA)
2016: Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play - Portola Pharmaceuticals (NASDAQ:PTLA)
2016: Portola Set For Big Gains - Portola Pharmaceuticals (NASDAQ:PTLA)
2016: Portola: Bitten Off More Than It Can Chew? - Portola Pharmaceuticals (NASDAQ:PTLA)
2016: What's Up With Portola? - Portola Pharmaceuticals (NASDAQ:PTLA)